<doc>
  <docmeta id="113s959is">
    <bill congress="113" type="s" number="959" version="is"/>
    <revision size="73881" annotations="0" status="complete" id="7" commit-time="2013-09-03T23:10:37Z" committer="mbohmer" doc="113s959is/7.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public">
	<metadata>
<dublinCore>
<title>113 S959 IS: Pharmaceutical Compounding Quality and Accountability Act</title>
<publisher>U.S. Senate</publisher>
<date>2013-05-15</date>
<format>text/xml</format>
<language>EN</language>
<rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">II</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>S. 959</legis-num>
		<current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
		<action>
			<action-date date="20130515">May 15, 2013</action-date>
			<action-desc>
        <sponsor name-id="S172">Mr. Harkin</sponsor> (for himself,
			 <cosponsor name-id="S289">Mr. Alexander</cosponsor>, <cosponsor name-id="S260">Mr. Roberts</cosponsor>, <cosponsor name-id="S332">Mr.
			 Franken</cosponsor>, and <cosponsor name-id="S182">Ms. Mikulski</cosponsor>)
			 introduced the following bill; which was read twice and referred to the
			 <committee-name committee-id="SSHR00">Committee on Health, Education, Labor,
			 and Pensions</committee-name>
      </action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend the Federal Food, Drug, and Cosmetic Act with
		  respect to compounding drugs.</official-title>
	</form>
	<legis-body>
		<section id="S1" section-type="section-one">
      <enum>1.</enum>
      <header>Short
			 title; references in Act</header>
			<subsection id="id8ACC258572204D83A85EA1849E53718F">
        <enum>(a)</enum>
        <header>Short
			 title</header>
        <text display-inline="yes-display-inline">This Act may be cited
			 as the <quote>
            <short-title>Pharmaceutical Compounding
			 Quality and Accountability Act</short-title>
          </quote>.</text>
			</subsection>
      <subsection id="id21541D659B854E34B45AF7A32A158413">
        <enum>(b)</enum>
        <header>References in
			 Act</header>
        <text>Except as otherwise specified, amendments made by this Act to
			 a section or other provision of law are amendments to such section or other
			 provision of the <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act">Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/21/301/etseq">21 U.S.C. 301 et
			 seq.</cato:entity-ref>)</cato:entity>.</text>
			</subsection>
    </section>
    <section id="id7E19EFA14F4B4868A468C60F026D1740">
      <enum>2.</enum>
      <header>Regulation of
			 human and animal drug compounding</header>
			<subsection id="id3721FE4A11DE4BC59EDB730C55A347BC">
        <enum>(a)</enum>
        <header>Clarification
			 of new drug and new animal drug status</header>
        <text>For purposes of the
			 <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act">Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/301">
              <cato:entity-ref entity-type="uscode" value="usc/21/301/etseq">21 U.S.C. 301 et seq.</cato:entity-ref>
            </external-xref>)</cato:entity>, the terms
			 <quote>new drug</quote> (as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:201/ss:p">section 201(p) of such Act</cato:entity-ref>) and
			 <quote>new animal drug</quote> (as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:201/ss:v">section 201(v) of such Act</cato:entity-ref>) shall
			 include a compounded human drug and a compounded animal drug,
			 respectively.</text>
			</subsection>
      <subsection id="idA9E0FBDB0FBB4DF4A49C2AF54628A533">
        <enum>(b)</enum>
        <header>Regulation of
			 human and animal drug compounding</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A">Section 503A</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/353a">
              <cato:entity-ref entity-type="uscode" value="usc/21/353a">21 U.S.C. 353a</cato:entity-ref>
            </external-xref>)</cato:entity>
			 is amended to read as follows:</text>
				<quoted-block display-inline="no-display-inline" id="idB47FC16A0245444EA736D7F23B24F1D1" style="OLC">
					<section id="idE07EB9835DF84C7DAFCF5DC95A117686">
            <enum>503A.</enum>
            <header>Human and
				animal drug compounding</header>
						<subsection id="id124AC6E0C1C04219970442F4C28E98BA">
              <enum>(a)</enum>
              <header>Scope</header>
							<paragraph id="id69BD248E560D4070A2A7680A26813ADE">
                <enum>(1)</enum>
                <header>Compounding</header>
                <text>In
				this section, the terms <term>compounding</term> and
				<term>compound</term>—</text>
								<subparagraph id="idCF793E06B2BE4B3FB31A2D7C6526E526">
                  <enum>(A)</enum>
                  <text>include—</text>
									<clause id="id743AE1FA4C0E42198D7740AC4F2EA2C9">
                    <enum>(i)</enum>
                    <text>the combining,
				admixing, mixing, diluting, reconstituting, or otherwise altering of a marketed
				drug;</text>
									</clause>
                  <clause id="id2CD6F08226F44A0D82CC25E137729990">
                    <enum>(ii)</enum>
                    <text>compounding a
				drug from a bulk drug substance; and</text>
									</clause>
                  <clause id="idA522786264244150859106801D9745FD">
                    <enum>(iii)</enum>
                    <text>repackaging, as
				defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:5" proposed="true">subsection (b)(5)</cato:entity-ref>; and</text>
									</clause>
                </subparagraph>
                <subparagraph id="id79E6A4A9124843DEA4E25E62C77D6431">
                  <enum>(B)</enum>
                  <text>exclude mixing,
				reconstituting, or other such acts with respect to a marketed drug that are
				limited to and performed solely in accordance with specific directions for such
				acts contained in approved labeling provided by a drug’s manufacturer, when
				performed upon receipt of a prescription order for an identified individual
				patient.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="idDB8DF24CECA14CB1B6558BD84C478822">
                <enum>(2)</enum>
                <header>Dispensing not
				a sale</header>
                <text>In this section, the terms <term>sell</term> or
				<term>resale</term> do not include dispensing to patients, or, in the case of
				animal drugs, to the individual responsible for providing care for the animal
				for which the drug is intended, in accordance with State law, including any fee
				associated with such dispensing.</text>
							</paragraph>
              <paragraph id="idF0ACB41105174CA2B39439C192726FCE">
                <enum>(3)</enum>
                <header>Exemptions</header>
                <text>This
				section shall not apply to—</text>
								<subparagraph id="id677477944B45431999200DB6EE0EFD30">
                  <enum>(A)</enum>
                  <text>medical
				gases;</text>
								</subparagraph>
                <subparagraph id="id4BDBC6F85E404AC08AE5DEB6ED190072">
                  <enum>(B)</enum>
                  <text>animal drugs that
				are subject to regulation as biological products by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1200">Secretary of
				Agriculture</cato:entity-ref> under the Act commonly known as the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Virus-Serum-Toxin Act">Virus-Serum-Toxin Act</cato:entity-ref>;
				or</text>
								</subparagraph>
                <subparagraph id="id3D59E4A42AEB4A058EFF0FA7D542035F">
                  <enum>(C)</enum>
                  <text>human blood and
				blood components for transfusion.</text>
								</subparagraph>
              </paragraph>
            </subsection>
            <subsection id="idDD20BCCAB9664E798DBF7C6632E7F85B">
              <enum>(b)</enum>
              <header>Definitions</header>
              <text>In
				this section:</text>
							<paragraph commented="no" id="id997D23D17191491D89FBFDEC74806287">
                <enum>(1)</enum>
                <header>Compounding
				manufacturer</header>
								<subparagraph commented="no" id="idDDE1701134694C26B76AA2D207CCF86E">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>The term <term>compounding manufacturer</term> means a
				facility at one geographic location or address—</text>
									<clause commented="no" id="id6C27B5F97EEE46FD8EEC39A3F21C52DD">
                    <enum>(i)</enum>
                    <text>that compounds
				any sterile drug product without receiving a prescription order for such
				sterile drug product prior to beginning compounding, and distributes or offers
				to sell such compounded sterile drug product in interstate commerce; or</text>
									</clause>
                  <clause commented="no" id="idAB3BAAAA0F7448589213D2825F1A1354">
                    <enum>(ii)</enum>
                    <text>that repackages
				any preservative-free sterile drug product or pools any sterile drug products,
				except as provided in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:7/sp:B" proposed="true">paragraph (7)(B)</cato:entity-ref>.</text>
									</clause>
                </subparagraph>
                <subparagraph commented="no" id="idAF7B050D7E88489E91892A734C70EB43">
                  <enum>(B)</enum>
                  <header>Excluded
				activities</header>
                  <text>Notwithstanding <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:1/sp:A/cl:ii" proposed="true">subparagraph (A)(ii)</cato:entity-ref>, a facility shall
				not be considered a compounding manufacturer if such facility—</text>
									<clause commented="no" id="id6D8DB87DFE854CB68F6870419C69C15A">
                    <enum>(i)</enum>
                    <text>repackages drugs
				in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:506F">section 506F</cato:entity-ref> or the final guidance described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:506F/ss:d">section
				506F(d)</cato:entity-ref>; and</text>
									</clause>
                  <clause commented="no" id="idD9F9FE13577B4CA89808ED5695E9C45A">
                    <enum>(ii)</enum>
                    <text>does not
				otherwise meet the definition of compounding manufacturer under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:1/sp:A" proposed="true">subparagraph
				(A)</cato:entity-ref>.</text>
									</clause>
                </subparagraph>
              </paragraph>
              <paragraph commented="no" id="id623299A87E57435B8DEA7B4F245D4D6E">
                <enum>(2)</enum>
                <header>Pooling;
				pools</header>
                <text>The terms <term>pooling</term> and
				<term>pool</term>—</text>
								<subparagraph commented="no" id="id6B2CBCE2FA774D859D9D198AA977298E">
                  <enum>(A)</enum>
                  <text>mean taking a
				single drug approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">section 505</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512">512</cato:entity-ref>, conditionally approved under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:571">section 571</cato:entity-ref>, included on the index established under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:572/ss:a/p:1">section 572(a)(1)</cato:entity-ref>, or
				licensed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:351">section 351 of the Public Health Service Act</cato:entity-ref> from the container
				in which it is distributed by the original manufacturer and combining it with
				the same drug from one or more other containers without or before further
				manipulating the product (such as by diluting it or mixing it with another,
				different drug or drugs);</text>
								</subparagraph>
                <subparagraph commented="no" id="idFC156E6EDE9C43D282048AAFAB965A0B">
                  <enum>(B)</enum>
                  <text>do not include
				combining the drug from two or more separate containers of the same drug when a
				single container of the drug is not sufficient to prepare a single dose for
				administration to an individual patient; and</text>
								</subparagraph>
                <subparagraph commented="no" id="idAA22CDC4EC61454F939C294463A5D191">
                  <enum>(C)</enum>
                  <text>do not include
				combining the drug from two or more separate containers of component products
				of a total parenteral nutrition product, if such pooling, and labeling and use
				of the finished total parenteral nutrition product, comply with State pharmacy
				law.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" id="id9A507F19BC7144BBBFD05655FCB5E324">
                <enum>(3)</enum>
                <header>Practitioner</header>
                <text>The
				term <term>practitioner</term> includes a physician, veterinarian, or any other
				person that is authorized to prescribe medication under State law.</text>
							</paragraph>
              <paragraph commented="no" id="id1E27EC8457A64DB2B5D1FD1BE3D0BD0A">
                <enum>(4)</enum>
                <header>Prescription;
				prescription order</header>
                <text>The term <term>prescription</term> or
				<term>prescription order</term> means a prescription or prescription order, as
				defined under applicable State law, that complies with requirements applicable
				under such State law.</text>
							</paragraph>
              <paragraph commented="no" id="id21CDB1BA3A8E4F0B8E1CE97AF20459DF">
                <enum>(5)</enum>
                <header>Repackage or
				repackaging</header>
                <text>The term <term>repackage</term> or
				<term>repackaging</term> means taking a drug approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">section 505</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512">512</cato:entity-ref>,
				conditionally approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:571">section 571</cato:entity-ref>, included on the index established
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:572/ss:a/p:1">section 572(a)(1)</cato:entity-ref>, or licensed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:351">section 351 of the Public Health
				Service Act</cato:entity-ref> from the container in which it is distributed by the original
				manufacturer and placing it in a different container of the same or smaller
				size without further manipulating the drug (such as by diluting it or mixing it
				with another, different drug or drugs), unless such repackaging is done
				pursuant to a prescription for an identified individual patient.</text>
							</paragraph>
              <paragraph commented="no" id="idCE32000E5D2A4E67A229ACB28ADCE88D">
                <enum>(6)</enum>
                <header>Sterile drug
				product</header>
                <text>The term <term>sterile drug product</term> means a drug
				that is—</text>
								<subparagraph commented="no" id="id2A1A2FFA331B46CBABF4D482B1C297DF">
                  <enum>(A)</enum>
                  <text>intended for
				parenteral administration;</text>
								</subparagraph>
                <subparagraph commented="no" id="idE3172D2848704D31ACA8D2A1E19EA6DF">
                  <enum>(B)</enum>
                  <text>an ophthalmic or
				inhalation drug; or</text>
								</subparagraph>
                <subparagraph commented="no" id="id7419382B9DB64E7CB7B47E497D128C67">
                  <enum>(C)</enum>
                  <text>required to be
				sterile under Federal or State law.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" id="id410980F3625745EC9972151B917D822F">
                <enum>(7)</enum>
                <header>Traditional
				compounder</header>
								<subparagraph commented="no" id="id3B9501FEA4BB4724AAA3964C932A65E2">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>The term <term>traditional compounder</term> means an
				entity—</text>
									<clause id="idfbb004eb9ee14dc29877477b50f3ee6b">
                    <enum>(i)</enum>
                    <text>wherein a drug is
				compounded by—</text>
										<subclause id="idf578b68c17e44a4cb168aae084dbff2b">
                      <enum>(I)</enum>
                      <text>a licensed
				pharmacist, or other pharmacy personnel (to the extent permitted under State
				law), in a State-licensed pharmacy or a Federal facility; or</text>
										</subclause>
                    <subclause id="idc7f9d6b19ed341aeaf87cedf5ac3c9fb">
                      <enum>(II)</enum>
                      <text>a licensed
				physician or licensed veterinarian, to the extent permitted under State
				law;</text>
										</subclause>
                  </clause>
                  <clause id="id72e1ac26cc6244108fb41bf5d84491e7">
                    <enum>(ii)</enum>
                    <text>that—</text>
										<subclause id="idF74B050AC47A4F679665A2245371C6AB">
                      <enum>(I)</enum>
                      <text>compounds a drug
				upon receipt of a prescription order for an identified individual patient;
				or</text>
										</subclause>
                    <subclause commented="no" id="id0922AEE1A8CF4215BE241F78F6DE9B31">
                      <enum>(II)</enum>
                      <text>compounds a drug
				in limited quantities before receipt of a prescription order for an identified
				individual patient, to the extent permitted under State law, if such
				compounding is based on a history of the licensed pharmacist, licensed
				physician, or licensed veterinarian receiving prescription orders for the
				compounding of the drug, which orders have been generated solely within an
				established relationship between the licensed pharmacist, licensed physician,
				or licensed veterinarian and—</text>
											<item commented="no" id="id7B6A562DF5E145A984E0C67A4EABC6D4">
                        <enum>(aa)</enum>
                        <text>such individual
				patient for whom the prescription order will be provided, or, in the case of an
				animal drug, such individual responsible for providing care for the animal for
				which the drug is ordered; or</text>
											</item>
                      <item id="idDF65B5F40E7F4160A479610C15A860F0">
                        <enum>(bb)</enum>
                        <text>the licensed
				physician, licensed veterinarian, or other licensed practitioner who will write
				such prescription order; and</text>
											</item>
                    </subclause>
                  </clause>
                  <clause commented="no" id="idd1bc3823bd5349409d0b0cfe12b07c31">
                    <enum>(iii)</enum>
                    <text>that does not
				meet the definition of a compounding manufacturer under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:1" proposed="true">paragraph (1)</cato:entity-ref>.</text>
									</clause>
                </subparagraph>
                <subparagraph commented="no" id="id4fb5a2b0e8d64003991312ef5c0dba59">
                  <enum>(B)</enum>
                  <header>Exceptions</header>
									<clause commented="no" id="id89348358A8F7472CB12861EC80C931CE">
                    <enum>(i)</enum>
                    <header>Hospitals and
				health systems</header>
										<subclause commented="no" id="id9A9E7AC43A8C42CDA7BB07607861BD83">
                      <enum>(I)</enum>
                      <header>In
				general</header>
                      <text>A pharmacy within a hospital, veterinary hospital, or
				health system that compounds a drug and dispenses such drug (which may include
				interstate shipment) within such hospital or health system or ships such drug
				for dispensing to patients with an established relationship with the hospital
				or health system (which may include interstate shipment), or that repackages
				preservative-free sterile drug product or pools sterile drug products, shall be
				considered a traditional compounder if such pharmacy otherwise meets the
				definition under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:7/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>.</text>
										</subclause>
                    <subclause commented="no" id="idC873139368D648A191D90864BA539C83">
                      <enum>(II)</enum>
                      <header>Health system
				defined</header>
                      <text>For purposes of this subparagraph, the term <term>health
				system</term> means two or more hospitals or veterinary hospitals that are
				owned and operated by the same entity and that share access to databases with
				drug order information for patients or animals, as applicable. A health system
				includes both the inpatient and outpatient facilities of hospitals within the
				health system.</text>
										</subclause>
                  </clause>
                  <clause commented="no" id="id4254BC5B2EB944BC9E494758DE8B7E11">
                    <enum>(ii)</enum>
                    <header>PET and
				radiopharmaceuticals</header>
                    <text>A pharmacy that compounds positron emission
				tomography drugs or radiopharmaceuticals shall be considered a traditional
				compounder if it does not compound other drugs that would cause it to be a
				compounding manufacturer described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:1/sp:A" proposed="true">paragraph (1)(A)</cato:entity-ref>.</text>
									</clause>
                </subparagraph>
              </paragraph>
            </subsection>
            <subsection id="id68E8D19962D245109458F8997CCEADAB">
              <enum>(c)</enum>
              <header>Exemptions from
				certain requirements</header>
							<paragraph id="idD5C461E3CF364B4FA82EEEA954D5CE0E">
                <enum>(1)</enum>
                <header>Drugs
				compounded by traditional compounders</header>
                <text>
                  <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:501/ss:a/p:2/sp:B">Sections 501(a)(2)(B)</cato:entity-ref>,
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:502/ss:f/p:1">502(f)(1)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">505</cato:entity-ref> (in the case of a human drug), <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512">section 512</cato:entity-ref> (in the case of an
				animal drug), and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:351">section 351 of the Public Health Service Act</cato:entity-ref> (in the case of
				a biological product) shall not apply to a compounded drug if such drug—</text>
								<subparagraph id="idAFE6CF4A1E854AB08A028FDBDEC7CBF9">
                  <enum>(A)</enum>
                  <text>is compounded by
				a traditional compounder that is in compliance with this section; and</text>
								</subparagraph>
                <subparagraph id="id93126E8B6795458996584A7EC608C561">
                  <enum>(B)</enum>
                  <text>meets the
				requirements of this section applicable to drugs compounded by traditional
				compounders.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="id2C92B90EEF024CE694E5F0E8AB8B934B">
                <enum>(2)</enum>
                <header>Drugs
				compounded by compounding manufacturers</header>
                <text>
                  <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:502/ss:f/p:1">Sections 502(f)(1)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">505</cato:entity-ref>
				(in the case of a human drug), <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512">section 512</cato:entity-ref> (in the case of an animal drug), and
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:351">section 351 of the Public Health Service Act</cato:entity-ref> (in the case of a biological
				product) shall not apply to a compounded prescription drug if such drug—</text>
								<subparagraph id="id9A4FD255941449C88F9C2D7F2CF75685">
                  <enum>(A)</enum>
                  <text>is compounded by
				a compounding manufacturer—</text>
									<clause id="id4287B01B938B4B3094779C200B1BCD45">
                    <enum>(i)</enum>
                    <text>that is not
				licensed as a pharmacy in any State; and</text>
									</clause>
                  <clause id="idFF97E921A2494C9D9D7ECAB12246A1C9">
                    <enum>(ii)</enum>
                    <text>that is in
				compliance with this section; and</text>
									</clause>
                </subparagraph>
                <subparagraph id="id876394A169354A2BB99BCC233B6CB079">
                  <enum>(B)</enum>
                  <text>meets the
				requirements of this section applicable to drugs compounded by compounding
				manufacturers.</text>
								</subparagraph>
              </paragraph>
            </subsection>
            <subsection id="id9D65C932308C4CA1A4DAE9CED5164DDD">
              <enum>(d)</enum>
              <header>Drugs that may
				not be compounded</header>
							<paragraph id="id9BAE43418C2041569D9B65180E2D8ED1">
                <enum>(1)</enum>
                <header>In
				general</header>
                <text>The following drugs may not be compounded, except under
				conditions specified by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>:</text>
								<subparagraph id="id683580DDC0B746479134E18F294DE5FE">
                  <enum>(A)</enum>
                  <header>Drugs that are
				demonstrably difficult to compound</header>
                  <text>A drug or category of drugs
				that presents demonstrable difficulties for compounding, which may include a
				complex dosage form or biological product, as designated by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d/p:2" proposed="true">paragraph (2)</cato:entity-ref>.</text>
								</subparagraph>
                <subparagraph id="id42958634B4D8402C9295EEB6A18290F9">
                  <enum>(B)</enum>
                  <header>Marketed
				drugs</header>
                  <text>A drug, other than a biological product, that is a copy of
				a marketed drug approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">505</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512">512</cato:entity-ref>, conditionally approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:571">section
				571</cato:entity-ref>, or included on the index established under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:572/ss:a/p:1">section 572(a)(1)</cato:entity-ref>, except as
				provided in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d/p:3" proposed="true">paragraph (3)</cato:entity-ref>.</text>
								</subparagraph>
                <subparagraph id="idC888A8C0E6114B4C836C49FE65180E1F">
                  <enum>(C)</enum>
                  <header>Biological
				products</header>
                  <text>A drug that is a biological product, except as provided
				in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d/p:4" proposed="true">paragraph (4)</cato:entity-ref>.</text>
								</subparagraph>
                <subparagraph commented="no" id="ID4D0BE8B4A67348F5A3C1B494894DFDB7">
                  <enum>(D)</enum>
                  <header>Drugs removed
				for safety and efficacy</header>
                  <text>A drug that appears on a list published
				by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> in the Federal Register of drugs that have been withdrawn or
				removed from the market because such drug or components of such drug have been
				found to be unsafe or not effective, subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d/p:5" proposed="true">paragraph (5)</cato:entity-ref>.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" id="idB80B609678C84FF58C631D50C00C9092">
                <enum>(2)</enum>
                <header>Drugs that are
				demonstrably difficult to compound</header>
								<subparagraph commented="no" id="id108691FE8F4B4B638FEF8C42FB4C0BB5">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may promulgate a regulation that designates
				drugs or categories of drugs that are demonstrably difficult to compound that
				may not be compounded, or that may be compounded only under conditions
				specified by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>. Such regulation—</text>
									<clause commented="no" id="idD4E81B03C4BE4C709A42E3B096EFB256">
                    <enum>(i)</enum>
                    <text>may include the
				designation of drugs or categories of drugs that are complex dosage forms or
				biological products, such as extended release products, metered dose inhalers,
				transdermal patches, and sterile liposomal products; and</text>
									</clause>
                  <clause commented="no" id="id8C0EDC081E6E483FB8BC7D0B798A115A">
                    <enum>(ii)</enum>
                    <text>shall specify,
				for each drug included on the list, whether the prohibition or condition
				applies to the use of the drug in humans, animals, or both.</text>
									</clause>
                </subparagraph>
                <subparagraph commented="no" id="id884A5FC134954D8381624206B78E550C">
                  <enum>(B)</enum>
                  <header>Interim
				list</header>
									<clause commented="no" id="idDBAA2EAA2749495195AA75DBA6DB6833">
                    <enum>(i)</enum>
                    <header>In
				general</header>
                    <text>Before the effective date of the regulation promulgated
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d/p:2/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may designate drugs that are complex
				dosage forms or biological products that cannot be compounded by—</text>
										<subclause commented="no" id="id3F0ECA26028B42EEA4DD3ED993479558">
                      <enum>(I)</enum>
                      <text>publishing a
				notice of such drugs proposed for designation, including the rationale for such
				designation, in the Federal Register;</text>
										</subclause>
                    <subclause commented="no" id="idEC67BA0BFA74424ABC8EDF1684DD438A">
                      <enum>(II)</enum>
                      <text>providing a
				period of not less than 60 days for comment on the notice; and</text>
										</subclause>
                    <subclause commented="no" id="idEED32EC05C2D45259957852FBBBE330F">
                      <enum>(III)</enum>
                      <text>publishing a
				notice in the Federal Register designating the drugs that are complex dosage
				forms and biological products that cannot be compounded.</text>
										</subclause>
                  </clause>
                  <clause commented="no" id="id4AB88029E0A94DF6897B85CBE6478F90">
                    <enum>(ii)</enum>
                    <header>Sunset</header>
                    <text>Any
				notice provided under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d/p:2/sp:B/cl:i" proposed="true">clause (i)</cato:entity-ref> shall cease to have force or effect on the
				date that is 5 years after the date of enactment of the
				<short-title>
                        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Compounding Quality and Accountability Act">Pharmaceutical Compounding Quality and
				Accountability Act</cato:entity-ref>
                      </short-title> or on the effective date of the final
				regulation under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d/p:2/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>, whichever is earlier.</text>
									</clause>
                </subparagraph>
              </paragraph>
              <paragraph commented="no" id="idAE5F6C00E48644F6AF3D98B7DC3034CB">
                <enum>(3)</enum>
                <header>Exceptions
				regarding marketed drugs</header>
								<subparagraph commented="no" id="id1435EC34580D4AA79D435DB4E6E3CA18">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>A drug (other than a biological product) that is a copy
				of a marketed drug approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">505</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512">512</cato:entity-ref>, conditionally approved under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:571">section 571</cato:entity-ref>, or included on the index established under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:572/ss:a/p:1">section 572(a)(1)</cato:entity-ref>,
				including variations of such drug compounded from bulk substances, may be
				compounded only if—</text>
									<clause commented="no" id="id481F27E7F74145ED9732CA16C2E3069B">
                    <enum>(i)</enum>
                    <subclause commented="no" display-inline="yes-display-inline" id="idBC4050AD48EA4A99AD05B7BE5481B076">
                      <enum>(I)</enum>
                      <text>the compounded
				variation produces for the patient a clinical difference between the compounded
				drug and such marketed drug, as determined by the prescribing practitioner,
				and, prior to beginning compounding a variation of such drug, the facility
				compounding the variation receives a prescription order specifying that the
				variation may be compounded; or</text>
										</subclause>
                    <subclause commented="no" id="idA5585ADD81B9464E8DC17B3B2A50D6D5" indent="up1">
                      <enum>(II)</enum>
                      <item commented="no" display-inline="yes-display-inline" id="idDA7D6A8A77A04D5391073F9EDAE633AE">
                        <enum>(aa)</enum>
                        <text>such marketed drug, at
				the time of compounding a copy of such drug and at the time of distribution of
				the compounded drug, is on the drug shortage list under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:506E">section 506E</cato:entity-ref> (in the
				case of a human drug), on the Current Drug Shortages list for veterinary
				products maintained on the Internet Web site of the Food and Drug
				Administration (in the case of an animal drug), or in the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary’s</cato:entity-ref> sole
				discretion, has otherwise been identified by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> as in shortage such
				as in a specific region or on a drug shortage list maintained by a private
				party; and</text>
											</item>
                      <item commented="no" id="idCBCA5C0C21904F548F02972A8B4CA9C1" indent="up1">
                        <enum>(bb)</enum>
                        <text>the traditional compounder or the
				compounding manufacturer notifies the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> not later than 3 calendar days
				after beginning the compounding, unless the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> waives the notice
				requirement; and</text>
											</item>
                    </subclause>
                  </clause>
                  <clause commented="no" id="idC78F9D091AA04B5EA408C799FF79D653">
                    <enum>(ii)</enum>
                    <text>in the case of a
				marketed drug approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">section 505</cato:entity-ref> that is subject to a risk evaluation
				and mitigation strategy approved with elements to assure safe use pursuant to
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505–1">section 505–1</cato:entity-ref>, the entity compounding the drug demonstrates to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				that the entity will utilize controls that are comparable to the controls
				applicable under the relevant risk evaluation and mitigation strategy.</text>
									</clause>
                </subparagraph>
                <subparagraph commented="no" id="idC9CE09412EC446449DE4AC47C5FECC91">
                  <enum>(B)</enum>
                  <header>Exclusion</header>
                  <text>For
				purposes of this paragraph, repackaging a marketed drug approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">section
				505</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512">512</cato:entity-ref>, conditionally approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:571">section 571</cato:entity-ref>, or included on the index
				established under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:572/ss:a/p:1">section 572(a)(1)</cato:entity-ref>, does not make the repackaged drug a copy
				of such marketed drug.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" id="idD1CEF9DC91C844BC9ACA915D926723E4">
                <enum>(4)</enum>
                <header>Exceptions
				regarding biological products</header>
                <text>A drug that is a biological product
				may be compounded only if—</text>
								<subparagraph id="id2A859AB582984865A8F33131508CBB0E">
                  <enum>(A)</enum>
                  <text>such drug is
				compounded from a licensed biological product and the compounding does not
				involve combining or mixing the licensed biological product with—</text>
									<clause id="id3C591B4C264C425DAC97D914AB727286">
                    <enum>(i)</enum>
                    <text>a
				bulk drug substance; or</text>
									</clause>
                  <clause id="idA7F5A1287AD04E7DAF054323B2341831">
                    <enum>(ii)</enum>
                    <text>another,
				different drug or drugs approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">505</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512">512</cato:entity-ref>, conditionally approved under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:571">section 571</cato:entity-ref>, included on the index established under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:572/ss:a/p:1">section 572(a)(1)</cato:entity-ref>, or
				licensed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:351">section 351 of the Public Health Service Act</cato:entity-ref>, unless the
				compounding is limited to the combining, mixing, or diluting of licensed
				allergenic products; and</text>
									</clause>
                </subparagraph>
                <subparagraph id="id86A28F6A8F054D1E906D7A2950ED88BD">
                  <enum>(B)</enum>
                  <clause commented="no" display-inline="yes-display-inline" id="id5A8EC86B74A74A318890D21DB356524B">
                    <enum>(i)</enum>
                    <text>with respect to a
				traditional compounder, the compounded biological product produces for the
				patient a clinical difference between the compounded drug and the licensed
				biological product, as determined by the prescribing practitioner, and, prior
				to beginning compounding such drug, the facility compounding the variation
				receives a prescription order specifying that the biological product may be
				compounded;</text>
									</clause>
                  <clause id="id74F93AC177524B08AC8CE4FC00E8F06A" indent="up1">
                    <enum>(ii)</enum>
                    <text>with respect to a compounding
				manufacturer, the compounded variation biological product produces for the
				patient a clinical difference between the compounded drug and the licensed
				biological product, as determined by a licensed practitioner responsible for
				the patient’s care in a health care entity that provides medical services
				through licensed prescribers directly to patients, and, prior to beginning
				compounding such drug, the compounding manufacturer receives a duly authorized
				medical order from a hospital or health system specifying that the biological
				product may be compounded; or</text>
									</clause>
                  <clause id="id96F80EB163844D9DB6740CA1C6E171FE" indent="up1">
                    <enum>(iii)</enum>
                    <text>the compounded biological product
				is an allergenic product.</text>
									</clause>
                </subparagraph>
              </paragraph>
              <paragraph commented="no" id="id1E712E3DB5BC4E65B65A6DE69E770416">
                <enum>(5)</enum>
                <header>Requirement
				regarding drugs removed for safety or efficacy</header>
                <text>The list published
				by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> in the Federal Register of drugs that have been withdrawn or
				removed from the market, as described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d/p:1/sp:D" proposed="true">paragraph (1)(D)</cato:entity-ref>, shall specify
				whether a human drug on such list may, notwithstanding the inclusion on such
				list, be compounded for use in animals. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall update the lists
				described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e/p:2/sp:D" proposed="true">subparagraphs (D)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e/p:2/sp:E" proposed="true">(E) of subsection (e)(2)</cato:entity-ref>, as appropriate, to
				conform with the list described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d/p:1/sp:D" proposed="true">paragraph (1)(D)</cato:entity-ref>.</text>
							</paragraph>
            </subsection>
            <subsection id="idA26C9E119AB94D0E9C4EF67BEF7A6D47">
              <enum>(e)</enum>
              <header>Quality of drug
				ingredients</header>
							<paragraph id="idA3C6AB0C1CA54DA3BEB491EDDDD3B666">
                <enum>(1)</enum>
                <header>Human
				drugs</header>
                <text>A traditional compounder or a compounding manufacturer
				shall—</text>
								<subparagraph id="ID9C11ECEE5FA74D05A77BAAAEA173503E">
                  <enum>(A)</enum>
                  <text>compound a human
				drug using only bulk drug substances (as defined in regulations of the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> published at <external-xref legal-doc="usc" parsable-cite="usc/21/207">section 207.3(a)(4)</external-xref> of title 21, Code of Federal
				Regulations (or any successor regulations))—</text>
									<clause id="IDF12B697D3B224CCBA5BEF3D5BE77E849">
                    <enum>(i)</enum>
                    <text>that—</text>
										<subclause id="IDE6DB70F8D2A54DC1952C2CDBBA04AF4A">
                      <enum>(I)</enum>
                      <text>comply with the
				standards of an applicable United States Pharmacopoeia or National Formulary
				monograph, if a monograph exists and has not been identified under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e/p:6" proposed="true">paragraph
				(6)</cato:entity-ref>, and the United States Pharmacopoeia chapters on pharmacy
				compounding;</text>
										</subclause>
                    <subclause id="ID1EBD4FC4F6EF429AA3F850E0891BB835">
                      <enum>(II)</enum>
                      <text>if such a
				monograph does not exist, are drug substances that are components of drugs
				approved by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>; or</text>
										</subclause>
                    <subclause id="IDFF52C6DC676C4B57A3258D1CFF2A40F8">
                      <enum>(III)</enum>
                      <text>if such a
				monograph does not exist and the drug substance is not a component of a drug
				approved by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, that appear on a list developed by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				through regulations issued by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>;</text>
										</subclause>
                  </clause>
                  <clause id="IDA448CA33D2F74776B6E3669191AB75F5">
                    <enum>(ii)</enum>
                    <text>that are
				manufactured by an establishment that is registered under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510">section 510</cato:entity-ref>
				(including a foreign establishment that is registered under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510/ss:i">section 510(i)</cato:entity-ref>);
				and</text>
									</clause>
                  <clause id="ID4305EDCEBF7244C0885A94C2253A43EA">
                    <enum>(iii)</enum>
                    <text>that are
				accompanied by valid certificates of analysis for each specific lot of bulk
				drug substance; and</text>
									</clause>
                </subparagraph>
                <subparagraph commented="no" id="IDA7E2C87F84C7458B92DF996A79E56BCE">
                  <enum>(B)</enum>
                  <text>use ingredients
				(other than bulk drug substances) that comply with the standards of an
				applicable United States Pharmacopoeia or National Formulary monograph, if a
				monograph exists and has not been identified under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e/p:6" proposed="true">paragraph (6)</cato:entity-ref>, and with the
				United States Pharmacopoeia chapter on pharmacy compounding.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" id="id62D837E76DF74F37864249856A72A773">
                <enum>(2)</enum>
                <header>Animal
				drugs</header>
                <text>A traditional compounder or a compounding manufacturer
				shall—</text>
								<subparagraph id="ide98f91f0616f40bcac33fe596184c29e">
                  <enum>(A)</enum>
                  <text>compound an
				animal drug using only bulk drug substances (as defined in regulations of the
				Secretary published at <external-xref legal-doc="usc" parsable-cite="usc/21/207">section 207.3(a)(4)</external-xref> of title 21, Code of Federal
				Regulations (or any successor regulations)) that—</text>
									<clause id="id5e47029fde46483395e9bde38852695d">
                    <enum>(i)</enum>
                    <text>are manufactured
				by an establishment that is registered under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510">section 510</cato:entity-ref> (including a foreign
				establishment that is registered under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510/ss:i">section 510(i)</cato:entity-ref>); and</text>
									</clause>
                  <clause id="idbb3e48471d20427d94a0e9af96fefbb6">
                    <enum>(ii)</enum>
                    <text>are accompanied
				by valid certificates of analysis for each specific lot of bulk drug
				substance;</text>
									</clause>
                </subparagraph>
                <subparagraph id="idA7F55762CD6D44D19C91579496485B85">
                  <enum>(B)</enum>
                  <text>use ingredients
				(other than bulk drug substances) that comply with the standards of an
				applicable United States Pharmacopoeia or National Formulary monograph, if a
				monograph exists and has not been identified under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e/p:6" proposed="true">paragraph (6)</cato:entity-ref>, and with the
				United States Pharmacopoeia chapters on pharmacy compounding;</text>
								</subparagraph>
                <subparagraph id="id7627130DE7A04EF5B9669617BB4EEC67">
                  <enum>(C)</enum>
                  <text>in the case of a
				compounded animal drug for use in non-food-producing minor species, use bulk
				substances that—</text>
									<clause id="idbc72f4ddd9ae497e8eac1cc6faba8d2c">
                    <enum>(i)</enum>
                    <text>comply with the
				standards of an applicable United States Pharmacopoeia or National Formulary
				monograph, if a monograph exists and has not been identified under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e/p:6" proposed="true">paragraph
				(6)</cato:entity-ref>, and with the United States Pharmacopoeia chapters on pharmacy
				compounding;</text>
									</clause>
                  <clause id="id44b69f6dc5ba49a08d5bcecdb00cbdcd">
                    <enum>(ii)</enum>
                    <text>if such a
				monograph does not exist, are drug substances that are components of drugs
				approved by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>; or</text>
									</clause>
                  <clause id="id10227604a6e34c768e005a8dc8521eee">
                    <enum>(iii)</enum>
                    <text>if such a
				monograph does not exist and the drug substance is not a component of a drug
				approved by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, that appear on a list developed by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				through regulations issued by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>;</text>
									</clause>
                </subparagraph>
                <subparagraph id="idA3E265515E3E4430B6C2AF2A8534FF0B">
                  <enum>(D)</enum>
                  <text>in the case of a
				compounded animal drug for use in non-food-producing major species, beginning
				on the date of publication of the list established in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e/p:3/sp:A" proposed="true">paragraph
				(3)(A)</cato:entity-ref>, shall use bulk substances that are included on such list, subject to
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e/p:3/sp:C" proposed="true">paragraph (3)(C)</cato:entity-ref>; and</text>
								</subparagraph>
                <subparagraph id="id7D5ECD0B44E546DFBEC16F5684AEAD70">
                  <enum>(E)</enum>
                  <text>in the case of a
				compounded animal drug for use in food-producing major and minor species, shall
				use bulk substances that are included on a list established by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> of
				bulk substances acceptable for use in compounding a drug for one or more such
				species, in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e/p:4" proposed="true">paragraph (4)</cato:entity-ref>.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="id673AA966C9BF4178B96C4BDE470F64BF">
                <enum>(3)</enum>
                <header>Non-food-producing
				major species listing procedure</header>
								<subparagraph id="id004D2BC59D9844C98CC8B27705FCD8A5">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>Not later than 30 days after the effective date of the
				<short-title>
                      <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Compounding Quality and Accountability Act" proposed="true">Pharmaceutical Compounding Quality and
				Accountability Act</cato:entity-ref>
                    </short-title>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall establish a list of bulk
				substances acceptable for compounding a drug for use in non-food-producing
				major species, and any conditions applicable to such use, and may also identify
				bulk substances that the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> has determined not acceptable for
				compounding with respect to a drug for use in such species.</text>
								</subparagraph>
                <subparagraph id="id7F9E5FD1328D43F3857518F907299572">
                  <enum>(B)</enum>
                  <header>Procedure</header>
                  <text>In
				developing and updating the list under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e/p:3/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				shall—</text>
									<clause id="idd12c0692831a4c50a37301967fc92f57">
                    <enum>(i)</enum>
                    <text>publish a notice
				in the Federal Register identifying bulk substances proposed as acceptable and
				any bulk substance determine to be unacceptable, and the rationale for such
				proposed designations;</text>
									</clause>
                  <clause id="id44af568875364a04a4b47e785f8a588b">
                    <enum>(ii)</enum>
                    <text>provide a period
				of not less than 30 days for comment on the notice; and</text>
									</clause>
                  <clause id="idad200469d99a40ea929c39c041b17f6a">
                    <enum>(iii)</enum>
                    <text>publish a
				notice in the Federal Register designating the bulk substances acceptable, and
				any bulk substances determined to be unacceptable, and the rationale for such
				designations and determinations.</text>
									</clause>
                </subparagraph>
                <subparagraph id="id622C237CC1C74E51AB1A95F4183B7E3F">
                  <enum>(C)</enum>
                  <header>Notification</header>
                  <text>Upon
				initial publication of the list under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e/p:3/sp:B/cl:iii" proposed="true">subparagraph (B)(iii)</cato:entity-ref>, any traditional
				compounder or compounding manufacturer that has received and filled a
				prescription in the 60 days prior to such publication for a compounded drug for
				a non-food-producing major species from a bulk substance not addressed in the
				notice (either as acceptable or unacceptable), and that reasonably expect to
				receive and fill another prescription for such a drug for such species within
				60 days after such publication, may notify the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> of such bulk substance
				within 30 days of such publication, in a manner to be determined by the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> and published in the Federal Register on or before publication of the
				list under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e/p:3/sp:B/cl:iii" proposed="true">subparagraph (B)(iii)</cato:entity-ref>. A traditional compounder or compounding
				manufacturer that provides such notice shall not be subject to the restriction
				in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e/p:2/sp:D" proposed="true">paragraph (2)(D)</cato:entity-ref> until such time as the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> designates such bulk
				substance as acceptable or determines it to be unacceptable pursuant to the
				process described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e/p:3/sp:B/cl:iii" proposed="true">subparagraph (B)(iii)</cato:entity-ref>.</text>
								</subparagraph>
                <subparagraph id="id4DE045D882034AB78D3FA14A8A43C5DB">
                  <enum>(D)</enum>
                  <header>Modification of
				list</header>
                  <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may amend the list at any time, in accordance
				with process described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e/p:3/sp:B" proposed="true">subparagraph (B)</cato:entity-ref>.</text>
								</subparagraph>
                <subparagraph id="idDBDE253FC8EC413D87062F90BC8F8900">
                  <enum>(E)</enum>
                  <header>Criteria</header>
                  <text>In
				evaluating bulk substances for purposes of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e/p:3/sp:B" proposed="true">subparagraph (B)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				shall consider, among other factors—</text>
									<clause id="idF11E00CC063543EFA45AF5E0E1E29753">
                    <enum>(i)</enum>
                    <text>the safety of the
				bulk substance;</text>
									</clause>
                  <clause id="idF041EFC729D04D29B6228C51720B58BD">
                    <enum>(ii)</enum>
                    <text>historical use
				of the substance in pharmacy compounding;</text>
									</clause>
                  <clause id="id8FEB07A930924B1782608F7334DE464C">
                    <enum>(iii)</enum>
                    <text>evidence of the
				effectiveness of the bulk substance or lack of effectiveness;</text>
									</clause>
                  <clause id="idC88B6BD87AB24B829C906E5A64B2B46F">
                    <enum>(iv)</enum>
                    <text>whether any drug
				approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">section 505</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512">512</cato:entity-ref>, conditionally approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:571">section 571</cato:entity-ref>, or
				included on the index established under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:572/ss:a/p:1">section 572(a)(1)</cato:entity-ref>, can be used on
				label, or any drug approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">section 505</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512">512</cato:entity-ref> can be used in an
				extralabel manner in accordance with section <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:a/p:4">paragraphs (4)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:a/p:5">(5) of section
				512(a)</cato:entity-ref>, to treat the applicable condition in the identified species; and</text>
									</clause>
                  <clause id="idF8DDA96C109042E6BEECCB640FB72059">
                    <enum>(v)</enum>
                    <text>whether a
				compounded drug appropriate to treat the applicable condition in the identified
				species could be obtained by manipulating a drug approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">505</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512">512</cato:entity-ref>,
				conditionally approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:571">section 571</cato:entity-ref>, or included on the index established
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:572/ss:a/p:1">section 572(a)(1)</cato:entity-ref>.</text>
									</clause>
                </subparagraph>
              </paragraph>
              <paragraph id="id18519C3B3CBB40ECA5017CC7DC8FB05C">
                <enum>(4)</enum>
                <header>Food-producing
				animals listing procedure</header>
                <text>In establishing a list of designated
				bulk substances acceptable for use in compounding a drug for use in
				food-producing major and minor species under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e/p:2" proposed="true">paragraph (2)</cato:entity-ref>, and any conditions
				applicable to such use, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall—</text>
								<subparagraph id="idb45c14775a4c4b6e8a44217c2f3281f2">
                  <enum>(A)</enum>
                  <text>publish a notice
				in the Federal Register identifying bulk substances proposed as acceptable and
				any bulk substance determine to be unacceptable, and the rationale for such
				designations;</text>
								</subparagraph>
                <subparagraph id="idbae007c8dd8f4136a816e0ced5e7015e">
                  <enum>(B)</enum>
                  <text>provide a period
				of not less than 30 days for comment on the notice; and</text>
								</subparagraph>
                <subparagraph id="id699a226e70714e8ba780994437cf0464">
                  <enum>(C)</enum>
                  <text>publish a notice
				in the Federal Register designating the bulk substances acceptable for use in
				compounding a drug for use in food-producing major and minor species, and the
				rationale for such designations.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="id5311468C28574984811043E6FE21D981">
                <enum>(5)</enum>
                <header>Withdrawal
				periods</header>
                <text>The requirements for establishing substantially extended
				withdrawal periods in accordance with <external-xref legal-doc="usc" parsable-cite="usc/21/530">section 530.20</external-xref> of title 21, Code of
				Federal Regulations (or any successor regulations) shall apply to compounded
				animal drugs for use in food-producing animals that are compounded using bulk
				substances.</text>
							</paragraph>
              <paragraph id="idC87C9E923A764B03B72468AF698F91A0">
                <enum>(6)</enum>
                <header>Identification
				by Secretary
                </header>
								<subparagraph id="idA27167AA14C344389AAA91A445F0E19E">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>Notwithstanding the existence of an applicable monograph
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e/p:1/sp:A/cl:i/scl:I" proposed="true">subparagraph (A)(i)(I)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e/p:1/sp:B" proposed="true">(B) of paragraph (1)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e/p:2/sp:B" proposed="true">subparagraph (B)</cato:entity-ref> or
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e/p:2/sp:C/cl:i" proposed="true">(C)(i) of paragraph (2)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may identify bulk substances that the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines, based on public health concerns, may not be used in
				compounding a drug.</text>
								</subparagraph>
                <subparagraph id="id4ECF80E150574AFE82373EAE986918E8">
                  <enum>(B)</enum>
                  <header>Procedure</header>
                  <text>In
				identifying the bulk substances that may not be used in compounding, the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall—</text>
									<clause commented="no" id="id4F4212AF65034BB0ABE1A10C7FB4AD36">
                    <enum>(i)</enum>
                    <text>publish a notice
				of such bulk substances proposed for identification in the Federal
				Register;</text>
									</clause>
                  <clause commented="no" id="idC6F3633DF918423CB0628ED6B990E737">
                    <enum>(ii)</enum>
                    <text>provide a period
				of not less than 60 days for comment on the notice;</text>
									</clause>
                  <clause commented="no" id="id771C4790F4684DB1988022FBB5E8AD05">
                    <enum>(iii)</enum>
                    <text>publish a
				notice in the Federal Register identifying the bulk substances that may not be
				used in compounding a drug; and</text>
									</clause>
                  <clause commented="no" id="id08A3C0901DF4453498566126140B5AA3">
                    <enum>(iv)</enum>
                    <text>state whether
				the bulk is not suitable for compounding of human drugs, animal drugs, or
				both.</text>
									</clause>
                </subparagraph>
              </paragraph>
            </subsection>
            <subsection id="id833A2EC3FBFE468B8D50C90196E09D5E">
              <enum>(f)</enum>
              <header>Requirements
				regarding wholesaling and labeling applicable to traditional compounders and
				compounding manufacturers</header>
							<paragraph id="id8667B99A4DA343CEA0421944645963DD">
                <enum>(1)</enum>
                <header>In
				general</header>
                <text>A compounded drug—</text>
								<subparagraph id="id9F80D551B3A9442CAF67B62CDF7A5B60">
                  <enum>(A)</enum>
                  <text>may not be sold
				by an entity other than the compounding manufacturer or traditional compounder
				that compounded the drug;</text>
								</subparagraph>
                <subparagraph id="id1454cdb6d39d480c880ae4f5aaae5834">
                  <enum>(B)</enum>
                  <text>compounded by a
				compounding manufacturer may not be sold to an entity other than a health care
				entity that provides medical services through licensed prescribers directly to
				patients or animals, or a network of such providers, except that a compounding
				manufacturer may transfer without profit a compounded sterile drug to a
				licensed pharmacy if—</text>
									<clause id="id32ED1352EB75411FB553D462098CC8C8">
                    <enum>(i)</enum>
                    <text>the licensed
				pharmacy falls under the same corporate ownership as the compounding
				manufacturer;</text>
									</clause>
                  <clause id="id7611569AED0E4920B40A1786D70876CC">
                    <enum>(ii)</enum>
                    <text>the transfer of
				such compounded sterile drug is solely for the purpose of dispensing the
				compounded sterile drug to the end user, who has been instructed by the
				prescribing physician to self-administer such compounded sterile drug;</text>
									</clause>
                  <clause id="idBE87C394F3DE4C9BBC4698CD7F3B54F2">
                    <enum>(iii)</enum>
                    <text>as of the date
				of enactment of the <short-title>
                        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Compounding Quality and Accountability Act" proposed="true">Pharmaceutical
				Compounding Quality and Accountability Act</cato:entity-ref>
                      </short-title>, the compounding
				manufacturer is an entity that provides pharmacy benefits management services
				on behalf of a health benefits plan;</text>
									</clause>
                  <clause id="ide819637ff124446ab94e9f5b32db9405">
                    <enum>(iv)</enum>
                    <text>the compounding
				manufacturer identifies itself to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> upon registering under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g/p:2" proposed="true">subsection (g)(2)</cato:entity-ref> as an entity that qualifies for the exemption under this
				subparagraph, and provides documentation of the compounding of such drugs as of
				the date of enactment of the <short-title>
                        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Compounding Quality and Accountability Act" proposed="true">Pharmaceutical
				Compounding Quality and Accountability Act</cato:entity-ref>
                      </short-title>, in a manner described
				by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>; and</text>
									</clause>
                  <clause id="id35a232a12b4042a8ba02f85b53dc5a5e">
                    <enum>(v)</enum>
                    <text>the compounding
				manufacturer receives confirmation from the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> that the compounding
				manufacturer qualifies for the exemption under this subparagraph and the
				sterile drug or drugs for which the exemption applies; and</text>
									</clause>
                </subparagraph>
                <subparagraph id="id007EBD3399A5440F8659169170BC4216">
                  <enum>(C)</enum>
                  <text>in the case of a
				compounded drug sold to a health care entity described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:f/p:1/sp:B" proposed="true">subparagraph (B)</cato:entity-ref>,
				shall be labeled <quote>not for resale</quote>.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="id72B54F427E5B4FF690CCA027A388E2DE">
                <enum>(2)</enum>
                <header>Advertising and
				promotion</header>
                <text>The advertising and promotion of compounded drugs shall
				not be false or misleading in any particular.</text>
							</paragraph>
            </subsection>
            <subsection id="idA1CF6C69CC38432C8CE3FB744EF3A80B">
              <enum>(g)</enum>
              <header>Other
				requirements applicable to compounding manufacturers</header>
							<paragraph id="idC2C2F2F332384A32B1F3F961DCA27047">
                <enum>(1)</enum>
                <header>Licensed
				pharmacist oversight</header>
                <text>A compounding manufacturer shall ensure that
				a pharmacist licensed in the State where the compounding manufacturer is
				located exercises direct supervision over the operations of the compounding
				manufacturer.</text>
							</paragraph>
              <paragraph id="id66BFC03B77664C5BA2C3C84B37514540">
                <enum>(2)</enum>
                <header>Registration of
				compounding manufacturers and reporting of drugs</header>
								<subparagraph id="id421F01E533DE4C6495C4A8BB825D3957">
                  <enum>(A)</enum>
                  <header>Registration of
				compounding manufacturers</header>
									<clause id="id55D2A2BD15664785B3156A02208583E0">
                    <enum>(i)</enum>
                    <header>Annual
				registration</header>
                    <text>During the period beginning on October 1 and ending
				on December 31 each year, each compounding manufacturer shall register with the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> its name, place of business, and unique facility identifier (which
				shall conform to the requirements for the unique facility identifier
				established under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510">section 510</cato:entity-ref>), and a point of contact e-mail address.</text>
									</clause>
                  <clause id="id4D1E5A1E60F84FCC9BB2069CA196916D">
                    <enum>(ii)</enum>
                    <header>New
				compounding manufacturers</header>
                    <text>Each compounding manufacturer, upon
				first engaging in the operations described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:1" proposed="true">subsection (b)(1)</cato:entity-ref>, shall
				immediately register with the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> and provide the information described
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g/p:2/sp:A/cl:i" proposed="true">clause (i)</cato:entity-ref>. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall establish a timeline for registration for
				the first year following the effective date of the
				<short-title>
                        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Pharmaceutical Compounding Quality and Accountability Act" proposed="true">Pharmaceutical Compounding Quality and
				Accountability Act</cato:entity-ref>
                      </short-title>. In no case may registration be required until
				at least 60 days following publication of the timeline in the Federal
				Register.</text>
									</clause>
                  <clause id="idF12E4B8D32A34B56ADDA893692F47877">
                    <enum>(iii)</enum>
                    <header>Additional
				facilities</header>
                    <text>Each compounding manufacturer duly registered in
				accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g/p:2/sp:A/cl:i" proposed="true">clauses (i)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g/p:2/sp:A/cl:ii" proposed="true">(ii)</cato:entity-ref> shall immediately identify to the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> any additional facility that engages in the activities described in
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:1" proposed="true">subsection (b)(1)</cato:entity-ref> and that is owned or operated in any State by the person that
				owns or operates the compounding manufacturer.</text>
									</clause>
                  <clause id="idE6108384DC254E90AF11B6F2A04A5B9E">
                    <enum>(iv)</enum>
                    <header>Availability
				of registration for inspection</header>
                    <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall make available
				for inspection, to any person so requesting, any registration filed pursuant to
				this subparagraph, except that any drug reporting information submitted
				pursuant to this subparagraph and the information accompanying such reporting
				shall be exempt from such inspection, unless the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> finds that such an
				exemption would be inconsistent with the protection of the public
				health.</text>
									</clause>
                </subparagraph>
                <subparagraph id="id2BDD2002550E4AEF8E20F578EBCFD917">
                  <enum>(B)</enum>
                  <header>Drug reporting
				by compounding manufacturers</header>
									<clause id="id79D78C95B30443CD97CCF7889C7A1704">
                    <enum>(i)</enum>
                    <header>In
				general</header>
                    <text>Each com­pound­ing manufacturer who registers with the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g/p:2/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> shall submit to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, once during the
				month of June of each year and once during the month of December of each year,
				a report—</text>
										<subclause id="id4E491B24598F408F97A107C169C65C20">
                      <enum>(I)</enum>
                      <text>identifying the
				drugs compounded by such compounding manufacturer during the previous 6-month
				period; and</text>
										</subclause>
                    <subclause id="id9E178B7CEB35439B8523C2F5EDF28D60">
                      <enum>(II)</enum>
                      <text>with respect to
				each drug identified under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g/p:2/sp:B/cl:i/scl:I" proposed="true">subclause (I)</cato:entity-ref>, providing the active ingredient, the
				source of such active ingredient, the National Drug Code number of the source
				drug or bulk active ingredient, the strength of the active ingredient per unit,
				the dosage form and route of administration, the package description, the
				number of individual units produced, the National Drug Code number of the final
				product, and which conforms to other applicable requirements identified by the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g/p:2/sp:B/cl:ii" proposed="true">clause (ii)</cato:entity-ref>.</text>
										</subclause>
                  </clause>
                  <clause id="idF983F6DC1A4241C998F39FCDE54F619C">
                    <enum>(ii)</enum>
                    <header>Form</header>
                    <text>Each
				report under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g/p:2/sp:B/cl:i" proposed="true">clause (i)</cato:entity-ref> shall be prepared in such form and manner as the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may prescribe by regulation or guidance.</text>
									</clause>
                </subparagraph>
                <subparagraph id="id76AA4E93AED944B88336D10189BE2A80">
                  <enum>(C)</enum>
                  <header>Electronic
				registration and reporting</header>
                  <text>Registrations and drug reporting under
				this paragraph (including the submission of updated information) shall be
				submitted to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> by electronic means unless the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> grants a
				request for waiver of such requirement because use of electronic means is not
				reasonable for the person requesting waiver.</text>
								</subparagraph>
                <subparagraph id="id1A157CED2E5E4E738F515EB1065B7CE0">
                  <enum>(D)</enum>
                  <header>Risk-based
				inspection frequency</header>
									<clause id="id6A6A6D7936F44888910435CA0A2AB587">
                    <enum>(i)</enum>
                    <header>In
				general</header>
                    <text>Compounding manufacturers shall be subject to inspection
				pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:704">section 704</cato:entity-ref>.</text>
									</clause>
                  <clause id="id95FC98A78AD34CCBAF3BE86B12A0DB0B">
                    <enum>(ii)</enum>
                    <header>Risk-based
				schedule</header>
                    <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, acting through one or more officers or
				employees duly designated by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, shall inspect compounding
				manufacturers described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g/p:2/sp:D/cl:i" proposed="true">clause (i)</cato:entity-ref> in accordance with a risk-based schedule
				established by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>.</text>
									</clause>
                  <clause id="id0A044EC7F35A42B8B438B9F7F2950F87">
                    <enum>(iii)</enum>
                    <header>Risk
				factors</header>
                    <text>In establishing the risk-based schedule under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g/p:2/sp:D/cl:ii" proposed="true">clause
				(ii)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall inspect compounding manufacturers according to the
				known safety risks of such compounding manufacturers, which shall be based on
				the following factors:</text>
										<subclause id="iddf7ad7d8bca24352a6c54bda15d6b340">
                      <enum>(I)</enum>
                      <text>The compliance
				history of the compounding manufacturer.</text>
										</subclause>
                    <subclause id="id669be2a27d274711abde0fd3d7fa5925">
                      <enum>(II)</enum>
                      <text>The record,
				history, and nature of recalls linked to the compounding manufacturer.</text>
										</subclause>
                    <subclause id="ideee744146b644e7faf6bf099a7f18545">
                      <enum>(III)</enum>
                      <text>The inherent
				risk of the drug compounded at the compounding manufacturer.</text>
										</subclause>
                    <subclause id="id5333a41d04664e27bcc45d90140e353b">
                      <enum>(IV)</enum>
                      <text>The inspection
				frequency and history of the compounding manufacturer, including whether the
				compounding manufacturer has been inspected pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:704">section 704</cato:entity-ref> within the
				last 4 years.</text>
										</subclause>
                    <subclause id="idfff4cdba7e524939a1f5515718d1a032">
                      <enum>(V)</enum>
                      <text>Any other
				criteria deemed necessary and appropriate by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> for purposes of
				allocating inspection resources.</text>
										</subclause>
                  </clause>
                </subparagraph>
              </paragraph>
              <paragraph id="id9537AC2124CD44C99DE9A3E16EF9CD9B">
                <enum>(3)</enum>
                <header>Adverse event
				reporting</header>
								<subparagraph id="idB9E1BC71ACC04D8BB89AC89AF587F7A2">
                  <enum>(A)</enum>
                  <header>Definitions</header>
                  <text>In
				this paragraph:</text>
									<clause id="idD6C72C0E69244B5C80B2ADA097A5ACD2">
                    <enum>(i)</enum>
                    <header>Adverse
				event</header>
                    <text>The term <term>adverse event</term> means any
				health-related event associated with the use of a compounded drug that is
				adverse, including—</text>
										<subclause id="idBDF4A3435B704D018BED4DD4D018DF82">
                      <enum>(I)</enum>
                      <text>an event
				occurring in the course of the use of the drug in professional practice;</text>
										</subclause>
                    <subclause id="idF1290E15DB084AF0958FDE6E547CAF28">
                      <enum>(II)</enum>
                      <text>an event
				occurring from an overdose of the drug, whether accidental or
				intentional;</text>
										</subclause>
                    <subclause id="idB5E137513FF845BA83B442E3D90E7B3F">
                      <enum>(III)</enum>
                      <text>an event
				occurring from abuse of the drug;</text>
										</subclause>
                    <subclause id="id0EDE3AE2211F45C7A4DEA30C4744231F">
                      <enum>(IV)</enum>
                      <text>an event
				occurring from withdrawal of the drug; and</text>
										</subclause>
                    <subclause id="id6CB54B1422254B769A931A8B0C53B3AF">
                      <enum>(V)</enum>
                      <text>any failure of
				expected pharmacological action of the drug.</text>
										</subclause>
                  </clause>
                  <clause id="id709065EB47584C41AE8C186A1A0B2E1F">
                    <enum>(ii)</enum>
                    <header>Serious
				adverse event</header>
                    <text>The term <term>serious adverse event</term> means
				an adverse event that—</text>
										<subclause id="idC27D838102D545148AA12428BFCDDE59">
                      <enum>(I)</enum>
                      <text>results
				in—</text>
											<item id="id707F247BC508464498B73C16CBEF99C7">
                        <enum>(aa)</enum>
                        <text>death;</text>
											</item>
                      <item id="id67D5890F9EE440FF94259B5DBAA8D596">
                        <enum>(bb)</enum>
                        <text>an
				adverse drug event that places the patient at immediate risk of death from the
				adverse drug event as it occurred (not including an adverse drug event that
				might have caused death had it occurred in a more severe form);</text>
											</item>
                      <item id="idFD5AA951FD1549E090DF2ECF24838530">
                        <enum>(cc)</enum>
                        <text>inpatient
				hospitalization or prolongation of existing hospitalization;</text>
											</item>
                      <item id="id7502DCE8F78647CE973914EE20D4A85A">
                        <enum>(dd)</enum>
                        <text>a
				persistent or significant incapacity or substantial disruption of the ability
				to conduct normal life functions; or</text>
											</item>
                      <item id="id7BF02EF5275841AABC502E9BC101331C">
                        <enum>(ee)</enum>
                        <text>a
				congenital anomaly or birth defect; or</text>
											</item>
                    </subclause>
                    <subclause id="id9A4C9B9A971046D0B70BE7F59BF3E854">
                      <enum>(II)</enum>
                      <text>based on
				appropriate medical judgment, may jeopardize the patient and may require a
				medical or surgical intervention to prevent an outcome described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g/p:3/sp:A/cl:ii/scl:I" proposed="true">subclause
				(I)</cato:entity-ref>.</text>
										</subclause>
                  </clause>
                </subparagraph>
                <subparagraph id="id0C33697C3DA74047B5F12E0E1AA3FC13">
                  <enum>(B)</enum>
                  <header>Reports</header>
									<clause id="id67869B18A5034A44A677FC89C2B0C6CF">
                    <enum>(i)</enum>
                    <header>Adverse event
				reporting requirement</header>
										<subclause id="idA887D231F05345EC90B0D51406572265">
                      <enum>(I)</enum>
                      <header>15-day
				report</header>
                      <text>If a compounding manufacturer becomes aware of any serious
				adverse event, such manufacturer shall submit reports of each instance to the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> as soon as practicable, but in no case later than 15 calendar days
				after the initial receipt of the applicable information. Such manufacturer
				shall investigate and submit to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> followup reports for each such
				instance not later than 15 calendar days after receipt of new information or as
				requested by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>. Unless and until the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> establishes the
				content and format of adverse event reports by guidance or regulation, reports
				shall be submitted in accordance with the content and format requirements under
				<external-xref legal-doc="regulation" parsable-cite="cfr/21/310.305">section 310.305</external-xref> of title 21, Code of Federal Regulations (or any successor
				regulations) (in the case of human drugs), <external-xref legal-doc="usc" parsable-cite="usc/21/600">section 600.80</external-xref> of title 21, Code of
				Federal Regulations (or any successor regulations) (in the case of biological
				products), or <external-xref legal-doc="regulation" parsable-cite="cfr/21/514.80">section 514.80</external-xref> of title 21, Code of Federal Regulations (or any
				successor regulations) (in the case of animal drugs).</text>
										</subclause>
                    <subclause id="id9B633185565A4948A6368D616B7887C3">
                      <enum>(II)</enum>
                      <header>Annual
				report</header>
                      <text>Compounding manufacturers that report serious adverse
				events shall submit in December of each year a narrative summary of any
				analysis of each report submitted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g/p:3/sp:B/cl:i/scl:I" proposed="true">subclause (I)</cato:entity-ref>, including a history of
				actions taken during the year because of each report, using the content,
				format, and manner established by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> by guidance or regulation.
				Until such time as the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> publishes such guidance or regulation, each
				compounding manufacturer shall retain such summaries as part of the records to
				be maintained in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g/p:3/sp:C" proposed="true">subparagraph (C)</cato:entity-ref>.</text>
										</subclause>
                  </clause>
                  <clause commented="no" id="id6D321165B54A4077BDFA7E5A6604A8C6">
                    <enum>(ii)</enum>
                    <header>Product
				quality reporting requirement</header>
                    <text>Not later than 3 calendar days
				after the compounding manufacturer becomes aware of information pertaining to
				sterility, stability, or other product quality concerns that could result in
				serious adverse events, the compounding manufacturer shall submit to the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> a product quality report, in a form and manner established by the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> by guidance or regulation.</text>
									</clause>
                </subparagraph>
                <subparagraph id="id44536B0037694181B0485E6C23AB0067">
                  <enum>(C)</enum>
                  <header>Maintenance of
				records</header>
                  <text>A compounding manufacturer shall maintain for a period of
				10 years records of all serious adverse drug events known to the compound
				manufacturer in accordance with <external-xref legal-doc="usc" parsable-cite="usc/21/314">section 314.80(i)</external-xref> of title 21, Code of Federal
				Regulations (or any successor regulation), or as otherwise directed by the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> in regulations.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="id0AA77FC0E39444BAB5F72E640E31C6A5">
                <enum>(4)</enum>
                <header>Labeling of
				drugs</header>
								<subparagraph id="id4160257BA70E4DB09C183EB7536E8BD5">
                  <enum>(A)</enum>
                  <header>Label</header>
                  <text>The
				label of a drug compounded by a compounding manufacturer shall include—</text>
									<clause id="idF9E7F797F950465EB7274D7887D5F8E3">
                    <enum>(i)</enum>
                    <text>the statement
				<quote>This is a compounded drug.</quote> or a reasonable comparable
				alternative statement (as specified by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>) that identifies the drug
				as a compounded drug;</text>
									</clause>
                  <clause id="idEB7899A57B684FA79D17102976B10755">
                    <enum>(ii)</enum>
                    <text>the name,
				address, and phone number of the applicable compounding manufacturer;
				and</text>
									</clause>
                  <clause id="idDA79C079705C49D680CB5D5A73939C49">
                    <enum>(iii)</enum>
                    <text>with respect to
				the compounded drug—</text>
										<subclause id="id62F76063D1DC4B87B46BD6271B486168">
                      <enum>(I)</enum>
                      <text>the lot or batch
				number;</text>
										</subclause>
                    <subclause id="idC016A9A56CF541FCAADB648774474679">
                      <enum>(II)</enum>
                      <text>the established
				name of the medication;</text>
										</subclause>
                    <subclause id="idD549A01C9C7D4090B1928597960B4E53">
                      <enum>(III)</enum>
                      <text>the dosage form
				and strength;</text>
										</subclause>
                    <subclause id="id35006F734B9A4EFE993F5315480589B6">
                      <enum>(IV)</enum>
                      <text>the statement of
				quantity or volume, as appropriate;</text>
										</subclause>
                    <subclause commented="no" id="idF155FE2DFFC943C8A890E6AECF0A334C">
                      <enum>(V)</enum>
                      <text>in the case of a
				drug intended for use in a food-producing animal, the withdrawal period
				established pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e/p:5" proposed="true">subsection (e)(5)</cato:entity-ref> to ensure that no residues from the
				compounded drug can be detected in edible tissues of the treated animal;</text>
										</subclause>
                    <subclause id="id9A4E22B47FF24DA58509C5A3AC0C3043">
                      <enum>(VI)</enum>
                      <text>the date that
				the drug was compounded;</text>
										</subclause>
                    <subclause id="idBA6A6BA1F5224E48BA527F9C9FA10EB3">
                      <enum>(VII)</enum>
                      <text>the expiration
				date;</text>
										</subclause>
                    <subclause id="id00ED99928063475198FD493712A63AD0">
                      <enum>(VIII)</enum>
                      <text>storage and
				handling instructions;</text>
										</subclause>
                    <subclause id="id89912486FA3E4795AC229EC8799C8346">
                      <enum>(IX)</enum>
                      <text>the National
				Drug Code number, if available;</text>
										</subclause>
                    <subclause id="id16D3AEFC29F849E9910F7BFC4F8F6706">
                      <enum>(X)</enum>
                      <text>the <quote>not
				for resale</quote> statement required as required by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:f/p:1/sp:C" proposed="true">subsection (f)(1)(C)</cato:entity-ref>;
				and</text>
										</subclause>
                    <subclause id="id4A5481B063E242438C52367809D2F800">
                      <enum>(XI)</enum>
                      <text>subject to
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g/p:4/sp:B/cl:i" proposed="true">subparagraph (B)(i)</cato:entity-ref>, a list of active and inactive ingredients, identified by
				established name and the quantity or proportion of each ingredient.</text>
										</subclause>
                  </clause>
                </subparagraph>
                <subparagraph id="idBF9D24476221410DB739170EA4A20223">
                  <enum>(B)</enum>
                  <header>Container</header>
                  <text>The
				container from which the individual units of a drug compounded by a compounding
				manufacturer are removed for dispensing or for administration (such as a
				plastic bag containing individual product syringes) shall include—</text>
									<clause id="id1D3436D0D1964BAEBD418037FA980897">
                    <enum>(i)</enum>
                    <text>the information
				described under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g/p:4/sp:A/cl:iii/scl:XI" proposed="true">subparagraph (A)(iii)(XI)</cato:entity-ref>, if there is not space on the label
				for such information;</text>
									</clause>
                  <clause id="idF2AD1B75764C47BA8843EF9FF7C35F09">
                    <enum>(ii)</enum>
                    <text>the following
				information to facilitate adverse event reporting: www.fda.gov/medwatch and
				1–800–FDA–1088; and</text>
									</clause>
                  <clause id="id402E5EEB89C74CD9BE1FD41ACA0510BD">
                    <enum>(iii)</enum>
                    <text>the directions
				for use, including dosage and administration, as appropriate.</text>
									</clause>
                </subparagraph>
                <subparagraph id="id2E2F356AB737472DADCF85AC0772A43B">
                  <enum>(C)</enum>
                  <header>Additional
				information</header>
                  <text>The label and labeling of a drug compounded by a
				compounding manufacturer shall include any other information as determined
				necessary and specified in regulations promulgated by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>.</text>
								</subparagraph>
              </paragraph>
            </subsection>
            <subsection id="idD8FB9353725F4B0CAF2CD7C4B706210C">
              <enum>(h)</enum>
              <header>Compounding
				manufacturer establishment and reinspection fees</header>
							<paragraph id="idFBE027F0B55B435B8358609AD0D8B6F1">
                <enum>(1)</enum>
                <header>Definitions</header>
                <text>In
				this subsection—</text>
								<subparagraph id="id0E812543AC0C4B628D41944F106355F2">
                  <enum>(A)</enum>
                  <text>the term
				<term>affiliate</term> has the meaning given such term in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:735/p:11">section
				735(11)</cato:entity-ref>;</text>
								</subparagraph>
                <subparagraph id="id05593E120B514D3EAB554172E2A92A80">
                  <enum>(B)</enum>
                  <text>the term
				<term>gross annual sales</term> means the total worldwide gross annual sales,
				in United States dollars, for a compounding manufacturer, including the sales
				of all the affiliates of the compounding manufacturer; and</text>
								</subparagraph>
                <subparagraph id="id1BBD8AD567AE484A8660B9D434340031">
                  <enum>(C)</enum>
                  <text>the term
				<term>reinspection</term> means, with respect to a compounding manufacturer,
				one or more inspections conducted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:704">section 704</cato:entity-ref> subsequent to an inspection
				conducted under such provision which identified noncompliance materially
				related to an applicable requirement of this Act, specifically to determine
				whether compliance has been achieved to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>'s satisfaction.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="id0AC78BF864B945B4B9A7296026CE7BF1">
                <enum>(2)</enum>
                <header>Establishment
				and reinspection fees</header>
                <text>For fiscal year 2015 and each subsequent
				fiscal year, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall, in accordance with this subsection, assess
				and collect—</text>
								<subparagraph id="idD0B43E623D4F4E5DA9978793DFCB5966">
                  <enum>(A)</enum>
                  <text>an annual
				establishment fee from each compounding manufacturer to cover
				inspection-related costs relating to inspections of drug compounders for such
				year; and</text>
								</subparagraph>
                <subparagraph id="id9EDA004698854CF885E6476F8590800E">
                  <enum>(B)</enum>
                  <text>a reinspection
				fee from each compounding manufacturer subject to a reinspection in such fiscal
				year.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="id6719D59CBC3643459A8CDBCA43374558">
                <enum>(3)</enum>
                <header>Establishment
				and reinspection fee setting</header>
                <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall establish the
				establishment and reinspection fee to be collected under this subsection for
				each fiscal year, based on the methodology described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:4" proposed="true">paragraph (4)</cato:entity-ref> and shall
				publish such fee in a Federal Register notice not later than 60 days before the
				start of each such year.</text>
							</paragraph>
              <paragraph id="id1054C35293E94A20A55797AD35A5B63E">
                <enum>(4)</enum>
                <header>Amount of
				establishment and reinspection fee</header>
								<subparagraph id="idC23EA184F02D4C9EA1EE4FCBAF700759">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>Except as provided in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:4/sp:D" proposed="true">subparagraph (D)</cato:entity-ref>, the amount of the
				annual establishment fee and the reinspection fee (if applicable) under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:2" proposed="true">paragraph (2)</cato:entity-ref> for each compounding manufacturer in a fiscal year shall be equal
				to the sum of—</text>
									<clause id="idD20AB76C5BC04657BE997C28041CF09F">
                    <enum>(i)</enum>
                    <subclause commented="no" display-inline="yes-display-inline" id="id1C21232DACE6477BBC689ECFEB746A81">
                      <enum>(I)</enum>
                      <text>$15,000 per compounding
				manufacturer, multiplied by</text>
										</subclause>
                    <subclause id="id5DABEF08D4EF48C0A72803614A4D5FF3" indent="up1">
                      <enum>(II)</enum>
                      <text>the inflation adjustment factor
				described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:4/sp:B" proposed="true">subparagraph (B)</cato:entity-ref>; plus</text>
										</subclause>
                  </clause>
                  <clause id="id188D198538E946DFA112125CA3D09F50">
                    <enum>(ii)</enum>
                    <text>the small
				business adjustment factor described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:4/sp:C" proposed="true">subparagraph (C)</cato:entity-ref>.</text>
									</clause>
                </subparagraph>
                <subparagraph id="idDE58CF307A464477992F58B17836C296">
                  <enum>(B)</enum>
                  <header>Inflation
				adjustment factor</header>
									<clause id="ID6E333A3737EA4C18B5D81B506A2CD4E5">
                    <enum>(i)</enum>
                    <header>In
				general</header>
                    <text>For fiscal year 2015 and subsequent fiscal years, the
				revenues established in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:4/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> shall be adjusted by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> by
				notice, published in the Federal Register, for a fiscal year by the amount
				equal to the sum of—</text>
										<subclause id="ID86599264058A44F785C46FEAB22F3EFA">
                      <enum>(I)</enum>
                      <text>one;</text>
										</subclause>
                    <subclause id="ID71524C26EF4E4DAFB92C29E93D94BDC6">
                      <enum>(II)</enum>
                      <text>the average
				annual percent change in the cost, per full-time equivalent position of the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref>, of all personnel compensation and benefits paid
				with respect to such positions for the first 3 years of the preceding 4 fiscal
				years, multiplied by the proportion of personnel compensation and benefits
				costs to total costs of an average full-time equivalent position of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food
				and Drug Administration</cato:entity-ref> for the first 3 years of the preceding 4 fiscal years,
				and</text>
										</subclause>
                    <subclause id="IDA60B05E9F00446FCA95561C70192E769">
                      <enum>(III)</enum>
                      <text>the average
				annual percent change that occurred in the Consumer Price Index for urban
				consumers (U.S. City Average; Not Seasonally Adjusted; All items; Annual Index)
				for the first 3 years of the preceding 4 years of available data multiplied by
				the proportion of all costs other than personnel compensation and benefits
				costs to total costs of an average full-time equivalent position of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food
				and Drug Administration</cato:entity-ref> for the first 3 years of the preceding 4 fiscal
				years.</text>
										</subclause>
                  </clause>
                  <clause id="ID8C4991E0CD3042B693EB4CACB0D9E9B6">
                    <enum>(ii)</enum>
                    <header>Compounded
				basis</header>
                    <text>The adjustment made each fiscal year under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:4/sp:B/cl:i" proposed="true">clause (i)</cato:entity-ref> shall
				be added on a compounded basis to the sum of all adjustments made each fiscal
				year after fiscal year 2014 under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:4/sp:B/cl:i" proposed="true">clause (i)</cato:entity-ref>.</text>
									</clause>
                </subparagraph>
                <subparagraph id="id8D2CB783774947D7A168BAB953D107C0">
                  <enum>(C)</enum>
                  <header>Small business
				adjustment factor</header>
                  <text>The small business adjustment factor described
				in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:4/sp:A/cl:ii" proposed="true">subparagraph (A)(ii)</cato:entity-ref> shall be an amount established by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> for
				each fiscal year based on the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>’s estimate of—</text>
									<clause id="idf96d564b5bc14f51b89b2c6a6b5be5af">
                    <enum>(i)</enum>
                    <text>the number of
				small businesses that will pay a reduced establishment fee for such fiscal
				year; and</text>
									</clause>
                  <clause id="id32d67b5fe01f44bc8b28926f847eead9">
                    <enum>(ii)</enum>
                    <text>the adjustment
				to the establishment fee necessary to achieve total fees equaling the total
				fees that the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> would have collected if no entity qualified for the
				small business exception in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:4/sp:D" proposed="true">subparagraph (D)</cato:entity-ref>.</text>
									</clause>
                </subparagraph>
                <subparagraph id="id29BAF1FF035D4E6688AEF1AEE562F685">
                  <enum>(D)</enum>
                  <header>Exception for
				small businesses</header>
									<clause id="id5BF05A8C2F5B43A4A7F08623C2952E5D">
                    <enum>(i)</enum>
                    <header>In
				general</header>
                    <text>In the case of a compounding manufacturer with gross
				annual sales of $1,000,000 or less in the 12 months ending June 1 of the fiscal
				year immediately preceding the fiscal year in which the fees under this
				subsection are assessed, the amount of the establishment fee and reinspection
				fee under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:2" proposed="true">paragraph (2)</cato:entity-ref> for a fiscal year shall be equal to
				<fraction>1/3</fraction> of the amount calculated under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:4/sp:A/cl:i" proposed="true">subparagraph (A)(i)</cato:entity-ref> in
				such fiscal year.</text>
									</clause>
                  <clause id="idABD9ACED9D2E443C9D9082AFCD35903D">
                    <enum>(ii)</enum>
                    <header>Application</header>
                    <text>The
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may require a small business to apply for the exception under this
				subparagraph by certifying its gross annual sales for the 12 months ending June
				1 of the fiscal year immediately preceding the fiscal year in which fees under
				this subsection are assessed. Any such application must be submitted to the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> prior to August 1 for the following fiscal year. Any statement or
				representation made to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall be subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/18/1001">section 1001 of title
				18, United States Code</cato:entity-ref>.</text>
									</clause>
                </subparagraph>
                <subparagraph id="id802D70D4249C48E6BA41B241D9774888">
                  <enum>(E)</enum>
                  <header>Crediting of
				fees</header>
                  <text>In establishing the small business adjustment factor under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:4/sp:C" proposed="true">subparagraph (C)</cato:entity-ref> for a fiscal year, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall provide for the
				crediting of fees from the previous year to the next year if the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				overestimated the amount of the small business adjustment factor for such
				previous fiscal year, and consider the need to account for any adjustment of
				fees and such other factors as the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines appropriate.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="id00B30E856F5F4EDCA8C17944D67BB9A5">
                <enum>(5)</enum>
                <header>Use of
				fees</header>
                <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall make all of the fees collected pursuant
				to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:2/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:2/sp:B" proposed="true">(B) of paragraph (2)</cato:entity-ref> available solely to pay for the
				inspection-related costs (including re-inspection) for the oversight of drug
				compounding.</text>
							</paragraph>
              <paragraph id="ide5364325e8034b1a86c67e90f8af77e6">
                <enum>(6)</enum>
                <header>Supplement not
				supplant</header>
                <text>Funds received by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> pursuant to this
				subsection shall be used to supplement and not supplant any other Federal funds
				available to carry out the activities described in this subsection.</text>
							</paragraph>
              <paragraph id="ID7A6A9D0587AC4CBE986A2BE6AC3FFE74">
                <enum>(7)</enum>
                <header>Crediting and
				availability of fees</header>
                <text>Fees authorized under this subsection shall
				be collected and available for obligation only to the extent and in the amount
				provided in advance in appropriations Acts. Such fees are authorized to remain
				available until expended. Such sums as may be necessary may be transferred from
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> salaries and expenses appropriation account
				without fiscal year limitation to such appropriation account for salaries and
				expenses with such fiscal year limitation. The sums transferred shall be
				available solely for the purpose of paying the inspection-related costs
				(including reinspection) for the oversight of drug compounding.</text>
							</paragraph>
              <paragraph id="ID84BCEC0EE2534EC0AAFFF080FC3C8F77">
                <enum>(8)</enum>
                <header>Collection of
				fees</header>
								<subparagraph id="idE1E8407602FD43A3BDB112066558EF95">
                  <enum>(A)</enum>
                  <header>Establishment
				fee</header>
                  <text>A compounding manufacturer shall remit the establishment fee
				due under this subsection in a fiscal year when submitting a registration
				pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g" proposed="true">subsection (g)</cato:entity-ref> for such fiscal year.</text>
								</subparagraph>
                <subparagraph id="ID5C0310B27F7E4602A1DD22A717221E39">
                  <enum>(B)</enum>
                  <header>Reinspection
				fee</header>
                  <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall specify in the Federal Register notice
				described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h/p:3" proposed="true">paragraph (3)</cato:entity-ref> the manner in which reinspection fees assessed under
				this subsection shall be collected and the timeline for payment of such fees.
				Such a fee shall be collected after the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> has conducted a reinspection
				of the compounding manufacturer involved.</text>
								</subparagraph>
                <subparagraph id="idCA36C67CD9A94D7593B21209A1F1199B">
                  <enum>(C)</enum>
                  <header>Effect of
				failure to pay fees</header>
									<clause id="id4721DF18986A44648676921A6864255A">
                    <enum>(i)</enum>
                    <header>Registration</header>
                    <text>A
				compounding manufacturer shall not be considered registered under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g" proposed="true">subsection
				(g)</cato:entity-ref> in a fiscal year until the date that the compounding manufacturer remits
				the establishment fee under this subsection for such fiscal year.</text>
									</clause>
                  <clause id="id0EAB03EFFE334F0FB4CEAA0DAA05F667">
                    <enum>(ii)</enum>
                    <header>Misbranding</header>
                    <text>All
				drugs compounded by a compounding manufacturer for which any establishment fee
				or reinspection fee has not been paid as required by this subsection shall be
				deemed misbranded under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:502/ss:cc">section 502(cc)</cato:entity-ref> until the fees owed for such
				compounding manufacturer under this subsection have been paid.</text>
									</clause>
                </subparagraph>
                <subparagraph id="IDD835A99A591A4272B9C3554ED59B5A64">
                  <enum>(D)</enum>
                  <header>Collection of
				unpaid fees</header>
                  <text>In any case where the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> does not receive
				payment of a fee assessed under this subsection within 30 days after it is due,
				such fee shall be treated as a claim of the United States Government subject to
				provisions of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc-chapter/31/37/II">subchapter II of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/31/37">chapter 37</external-xref> of title 31, United States
				Code</cato:entity-ref>.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" id="ID0A6668F2D1AC43238BF35D57E3032C90">
                <enum>(9)</enum>
                <header>Annual report
				to congress</header>
                <text>Not later than 120 days after each fiscal year in
				which fees are assessed and collected under this subsection, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				shall submit a report to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="SSHR00">Committee on Health, Education, Labor, and
				Pensions of the Senate</cato:entity-ref> and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="HIF00">Committee on Energy and Commerce of the House of
				Representatives</cato:entity-ref>, to include a description of fees assessed and collected for
				each year, a summary description of entities paying the fees, and the number of
				inspections and reinspections of such entities performed each year.</text>
							</paragraph>
              <paragraph id="ID00940E566BAF4BCAA03683F6C010BBF9">
                <enum>(10)</enum>
                <header>Authorization
				of appropriations</header>
                <text>
                  <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="auth-auth-approp">
                    <cato:funds-and-year amount="indefinite" year="2015,..">For fiscal year 2015 and each subsequent fiscal
				year</cato:funds-and-year>, there is authorized to be appropriated for fees under this subsection an
				amount equivalent to the total amount of fees assessed for such fiscal year
				under <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:h" proposed="true">this subsection</cato:entity-ref>.</cato:entity>
                </text>
							</paragraph>
            </subsection>
            <subsection commented="no" id="id0fd8d114d3264442917d796b95fe9936">
              <enum>(i)</enum>
              <header>Action by
				Secretary regarding complaints from State boards of pharmacy</header>
							<paragraph id="id8d3d69653815448f9c07e50fe468179f">
                <enum>(1)</enum>
                <header>Designation</header>
                <text>The
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall designate a point of contact and establish a format and
				procedure for a State Board of Pharmacy to notify the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> if it appears
				to a State Board of Pharmacy that an entity licensed by a State as a pharmacy
				is required to be registered with the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> as a compounding
				manufacturer.</text>
							</paragraph>
              <paragraph id="ide7fc305dcedd4b96ab0f8908ab885d23">
                <enum>(2)</enum>
                <header>Determination</header>
                <text>If
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines that such an entity described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:i/p:1" proposed="true">paragraph (1)</cato:entity-ref> is
				required to be registered with the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> as a compounding manufacturer, the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall transmit such determination to the State Board of Pharmacy in
				the State in which the entity is located, and to the State Board of Pharmacy in
				the notifying State, if different, within 15 days of such determination.</text>
							</paragraph>
              <paragraph id="idd1e3de8f0c724857988f1c04046e2b6d">
                <enum>(3)</enum>
                <header>Effect</header>
                <text>The
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall encourage direct communications between States regarding
				traditional compounders. Nothing in this subsection shall expand the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary’s</cato:entity-ref> authority over or responsibility for traditional
				compounding.</text>
							</paragraph>
            </subsection>
            <subsection id="idBC94F52C9BC041CD9D70142EA0CBB338">
              <enum>(j)</enum>
              <header>Prescription
				order reference</header>
              <text>For purposes of this section, reference to a
				prescription order for an identified individual patient includes, in the case
				of animal drugs, a prescription order for a specific herd or flock (or other
				identified group) of
				animals.</text>
						</subsection>
          </section>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</subsection>
      <subsection id="idB3D5A38BF4604BD2910BDDC6E0ADEA18">
        <enum>(c)</enum>
        <header>Prohibited
			 act</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:301">Section 301</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/331">
              <cato:entity-ref entity-type="uscode" value="usc/21/331">21 U.S.C. 331</cato:entity-ref>
            </external-xref>)</cato:entity> is amended—</text>
				<paragraph id="id7A14832EB8C1435489E8DD9F70C2E396">
          <enum>(1)</enum>
          <text>in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:301/ss:e">subsection
			 (e)</cato:entity-ref>, by striking <quote>
              <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:417">417</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:416">416</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:504">504</cato:entity-ref>
            </quote> and inserting <quote>
              <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:417">417</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:416">416</cato:entity-ref>,
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g" proposed="true">503A(g)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:504">504</cato:entity-ref>
            </quote>; and</text>
				</paragraph>
        <paragraph id="id4F611AF35DB04390893F9E21D418EF10">
          <enum>(2)</enum>
          <text>by adding at the
			 end the following:</text>
					<quoted-block display-inline="no-display-inline" id="idBAF5A9A10D1742DB9F1C8AFCBB8A1D23" style="OLC">
						<subsection id="id05F3DE114692403E955BC88352C2CA87">
              <enum>(ccc)</enum>
              <text>The resale of a
				compounded drug that is labeled <quote>not for resale</quote> as required by
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A" proposed="true">section
				503A</cato:entity-ref>.</text>
						</subsection>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
				</paragraph>
      </subsection>
      <subsection id="idF2B2954B49D24184A34078B8D8D700C7">
        <enum>(d)</enum>
        <header>Report by
			 GAO</header>
        <text>Not later than November 1, 2016, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0500">Comptroller General of
			 the United States</cato:entity-ref> shall conduct study and submit to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref> a report regarding
			 the impact of this Act (and the amendments made by this Act) on the safety of
			 animal drug compounding and the availability of safe and effective drugs for
			 animals.</text>
			</subsection>
    </section>
    <section id="id7198612A26904983A02CEDBD7F6F812C">
      <enum>3.</enum>
      <header>Other
			 requirements relating to compounding manufacturers</header>
			<subsection id="id66EB604B5AD848C0B9CF6B6B22E2CE9E">
        <enum>(a)</enum>
        <header>Labeling</header>
        <text display-inline="yes-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:502">Section 502</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/352">
              <cato:entity-ref entity-type="uscode" value="usc/21/352">21 U.S.C. 352</cato:entity-ref>
            </external-xref>)</cato:entity> is amended by
			 adding at the end the following:</text>
				<quoted-block display-inline="no-display-inline" id="id763EF671E5794D229D0C570CB18BF934" style="OLC">
					<subsection id="idF96D8B759C15433EB5C85A511CC5F631">
            <enum>(bb)</enum>
            <text>If it is a
				compounded drug and the labeling does not include the information as required
				by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:f/p:1/sp:C" proposed="true">subsections (f)(1)(C)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g/p:4" proposed="true">(g)(4) of section 503A</cato:entity-ref>, as applicable.</text>
					</subsection>
          <subsection id="id15EF37DE857C4A019473B0B540DF25A6">
            <enum>(cc)</enum>
            <text>If it is a drug,
				and it was compounded by a compounding manufacturer for which fees have not
				been paid as required by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:g" proposed="true">section
				503A(g)</cato:entity-ref>.</text>
					</subsection>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</subsection>
      <subsection id="id8A1FF9E1E4354A3196B3516BC7A5431A">
        <enum>(b)</enum>
        <header>Application of
			 inspection requirements to compounding manufacturers</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:704/ss:a/p:2">Section
			 704(a)(2)</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/374">
              <cato:entity-ref entity-type="uscode" value="usc/21/374/a/2">21 U.S.C. 374(a)(2)</cato:entity-ref>
            </external-xref>)</cato:entity> is amended by adding at the end the following
			 flush text:</text>
				<quoted-block display-inline="no-display-inline" id="idD905BE9E04294D2FAF4510F9751D906A" style="OLC">
					<quoted-block-continuation-text quoted-block-continuation-text-level="subsection">The
				exemption in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:704/ss:a/p:2/sp:A">subparagraph (A)</cato:entity-ref> does not apply with respect to compounding
				manufacturers (as such term is defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A" proposed="true">section
				503A</cato:entity-ref>).</quoted-block-continuation-text>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</subsection>
      <subsection id="id6C4CD85E10E040ACB3F6EADBDEC5670B">
        <enum>(c)</enum>
        <header>Adulteration of
			 compounded animal drugs containing drug residues</header>
        <text>
          <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:402/ss:a/p:2/sp:C">Section
			 402(a)(2)(C)</cato:entity-ref> is amended by striking <quote>
            <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512">512</cato:entity-ref>;</quote> and inserting
			 <quote>
            <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512">512</cato:entity-ref>; or (iii) any residue from a compounded animal drug;</quote>.</text>
			</subsection>
    </section>
    <section id="id310111ED2A9245A3BED7174E7D1C2811">
      <enum>4.</enum>
      <header>Implementation</header>
      <text display-inline="no-display-inline">In promulgating any regulations to implement
			 this Act (and the amendments made by this Act), the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary of Health and
			 Human Services</cato:entity-ref> shall—</text>
			<paragraph id="idfaa21d2a856d46b7b3b3c81f9530e1cd">
        <enum>(1)</enum>
        <text>issue a notice of
			 proposed rulemaking that includes the proposed regulation;</text>
			</paragraph>
      <paragraph id="idb08c95274883468194c989ad5d9cbe72">
        <enum>(2)</enum>
        <text>provide a period
			 of not less than 60 days for comments on the proposed regulation; and</text>
			</paragraph>
      <paragraph commented="no" display-inline="no-display-inline" id="idaecff12bfa6548d79f9f852978b98d21">
        <enum>(3)</enum>
        <text>publish the final
			 regulation not more than 18 months following publication of the proposed rule
			 and not less than 30 days before the effective date of such final
			 regulation.</text>
			</paragraph>
    </section>
    <section commented="no" display-inline="no-display-inline" id="idA41E64A175CA4A088F1F8B1EFFE7F414">
      <enum>5.</enum>
      <header>Effective
			 date</header>
      <text display-inline="no-display-inline">This Act (and the
			 amendments made by this Act) shall take effect on the date that is 1 year after
			 the date of enactment of this Act.</text>
		</section>
  </legis-body>
</bill>
</doc>